RT Journal Article
SR Electronic
T1 Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes
JF Evidence Based Medicine
JO Evid Based Med
FD BMJ Publishing Group Ltd
SP 168
OP 168
DO 10.1136/ebm.14.6.168
VO 14
IS 6
YR 2009
UL http://ebm.bmj.com/content/14/6/168.abstract
AB